Perospirone hydrochloride: The novel atypical antipsychotic agent with high affinities for 5-HT2, D2 and 5-HT1A receptors

Biogenic Amines

Volumn 18, Issue 3-6, 2004, Pages 307-317

  Ishibashi, Tadashi ^a   Ohno, Yukihiro ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

5 HT1A receptors; 5 HT2 receptors; Antipsychotic agents; D2 receptors; Extrapyramidal side effects; Perospirone

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DESIPRAMINE; DIAZEPAM; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; IMIPRAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OLANZAPINE; PEROSPIRONE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL MODEL; ARTICLE; BRADYKINESIA; CATALEPSY; CENTRAL NERVOUS SYSTEM DEPRESSION; DRUG MECHANISM; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; IN VIVO STUDY; MOOD DISORDER; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; NONHUMAN; ORTHOSTATIC HYPOTENSION; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RODENT; SCHIZOPHRENIA;

ANIMALIA; RODENTIA;

EID: 4344663852     PISSN: 01688561     EISSN: None     Source Type: Journal    
DOI: 10.1163/1569391041501906     Document Type: Article

References (27)

1. Brymaster, F. P., Calligara, D. O., Falcone, J. F., et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine, Neuropsychopharmacology 14, 87-96.
2. Ellenbroek, B. A., Peeters, B. W., Honig, W. M., et al. (1987). The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs, Psychopharmacology (Berlin) 93, 343-348.
3. 2 antagonistic actions, Jpn. J. Pharmacol. 53, 321-329.
4. Ishibashi, T., Ikeda, K., Ishida, K., et al. (1996). Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum, Eur. J. Pharmacol. 303, 247-251.
5. 2 receptor antagonist, on Fos protein expression in the rat forebrain, Pharmacol. Biochem. Behav. 63, 535-541.
6. Ishida-Tokuda, K., Ohno, Y., Sakamoto, H., et al. (1996). Effects of perospirone (SM-9018), a novel serotonin-2 and dopamine-2 receptor antagonist, and other antipsychotics in the conditioned fear stress-induced freezing behavior model in rats, Jpn. J. Pharmacol. 72, 119-126.
7. Jeste, D. V. and Caligiuri, M. P. (1993). Tardive dyskinesia, Schizophrenia Bull. 19, 303-315.
8. Kato, T., Hirose, A., Ohno, Y., et al. (1990). Binding profile of SM-9018, a novel antipsychotic candidate, Jpn. J. Pharmacol. 54, 478-481.
9. Leysen, J. E., Janssen, P. M. F., Gommeren, W., et al. (1992). In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone, Mol. Pharmacol. 41, 494-508.
10. Maruoka, Y., Ohno, Y., Kato, T., et al. (1993). Effects of SM-9018, a potential atypical neuroleptic, on the central monoaminergic system in rats, Jpn. J. Pharmacol. 62, 419-422.
11. Meltzer, H. Y. and Nash, J. F. (1991). Effects of antipsychotic drugs on serotonin receptors, Pharmacol. Rev. 43, 587-604.
12. 1A receptors, J. Pharmacol. Exp. Ther. 295, 853-861.
13. Murasaki, M., Koyama, T., Machiyama, Y., et al. (1997). Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia - A comparative double-blind study with haloperidol, Clin. Eval. 24, 159-205.
14. Noda, Y., Kamei, H., Mamiya, T., et al. (2000). Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and doparninergic functions, Neuropsychopharmacology 23, 375-387.
15. Ohno, Y. (2002). Pharmacological characteristics of the new atypical antipsychotic agents, serotonin-dopamine antagonists (SDA), Jpn. J. Clin. Psychopharmacol. 5, 147-153.
16. 2 receptor antagonist, using the mouse pole test, Pharmacol. Biochem. Behav. 49, 19-23.
17. 2 antagonist, on dopamine and 5-HT receptors in rats, Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 1091-1101.
18. 2 receptor blocking activity, Pharmacol. Biochem. Behav. 57, 889-895.
19. Ohno, Y., Matsumoto, K., Horisawa, T., et al. (2001). Jpn. J. Neuropsychopharmacol. 21, 345 (in Japanese).
20. Ohno, Y., Matsumoto, K. and Nakamura, M. (2002). Jpn. J. Neuropsychopharmacol. 22, 253 (in Japanese).
21. Robertson, G. S., Matsumura, H. and Fibiger, H. C. (1994). Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity, J. Pharmacol. Exp. Ther. 271, 1058-1066.
22. Sakamoto, H., Matsumoto, K., Ohno, Y., et al. (1998). Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent, Pharmacol. Biochem. Behav. 60, 873-878.
23. See, R. E. and Ellison, G. (1990). Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia, Eur. J. Pharmacol. 181, 175-186.
24. 1A receptor, J. Pharmacol. Sci. 93, 114-117.
25. 1A agonist tandospirone on memory functions in schizophrenia, J. Clin. Pharmacol. 20, 386-388.
26. Tokuda, K., Ohno, Y., Ishibashi, T., et al. (1997). Studies on central actions of perospirone hydrochloride, a novel antipsychotic agent, Clin. Rep. 31, 853-878.
27. Yabuuchi, K., Tagashira, R., Horisawa, T., et al. (1998). Jpn. J. Psychopharmacol. 18, 374 (in Japanese).